Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 3/20 | 0.51 |
| ▸ | CDK8 | P49336 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197715 | 0.88 | CCNC (0.53) | CCNCCDK8SMN1; SMN2TRPA1NR3C2 | |
| SCHEMBL24366083 | 0.87 | CCNC (0.49) | CCNCCDK8SMN1; SMN2TRPA1PRMT5 | |
| SCHEMBL2707270 | 0.85 | CCNC (0.50) | CCNCCDK8SMN1; SMN2TRPA1KMT2A | |
| SCHEMBL27580250 | 0.83 | CCNC (0.51) | CCNCCDK8SMN1; SMN2TRPA1KMT2A | |
| SCHEMBL29892279 | 0.83 | CCNC (0.51) | CCNCCDK8SMN1; SMN2TRPA1KMT2A | |
| SCHEMBL28149188 | 0.80 | TRPA1 (0.53) | CCNCCDK8TRPA1NR3C2KMT2A | |
| SCHEMBL17142311 | 0.78 | TRPA1 (0.51) | CCNCCDK8TRPA1NR3C2KMT2A | |
| SCHEMBL24366957 | 0.77 | PRMT5 (0.47) | PRMT5WDR77 | |
| SCHEMBL17454945 | 0.77 | CCNC (0.52) | CCNCCDK8SMN1; SMN2TRPA1RIPK1 | |
| SCHEMBL29212195 | 0.76 | RIPK1 (0.47) | CCNCCDK8SMN1; SMN2KMT2ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CCNC 1193/4885CDK8 3041/4885SMN1; SMN2 1943/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CCNC 1193/4885CDK8 3041/4885SMN1; SMN2 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.